Literature DB >> 14592775

Adenovirus E4-34kDa requires active proteasomes to promote late gene expression.

Kara A Corbin-Lickfett1, Eileen Bridge.   

Abstract

A complex of the Adenovirus (Ad) early region 1b 55-kDa protein (E1b-55kDa) and the early region 4 ORF6 34-kDa protein (E4-34kDa) promotes viral late RNA accumulation in the cytoplasm while inhibiting the transport of most newly synthesized cellular mRNA. The E4 ORF3 11-kDa protein (E4-11kDa) functionally compensates for at least some of the activities of this complex. We find that the same large central region of E4-34kDa that is required for proteasome-mediated degradation of p53 (J. Virol. 75, (2001) 699-709) is also required to promote viral late gene expression in a complementation assay. E4-34kDa does not promote late gene expression in complementation assays performed in the presence of proteasome inhibitors. A proteasome inhibitor also dramatically reduced late gene expression by a virus that lacks the E4-11kDa gene and therefore relies on E4-34kDa for late gene expression. Our results suggest that E4-34kDa activity in promoting late gene expression depends on the proteasome.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14592775     DOI: 10.1016/s0042-6822(03)00527-0

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  20 in total

1.  Both BC-box motifs of adenovirus protein E4orf6 are required to efficiently assemble an E3 ligase complex that degrades p53.

Authors:  Paola Blanchette; Chi Ying Cheng; Qin Yan; Gary Ketner; David A Ornelles; Thomas Dobner; Ronald C Conaway; Joan Weliky Conaway; Philip E Branton
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

2.  Adenovirus ubiquitin-protein ligase stimulates viral late mRNA nuclear export.

Authors:  Jennifer L Woo; Arnold J Berk
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

3.  Adenovirus E4 34k and E1b 55k oncoproteins target host DNA ligase IV for proteasomal degradation.

Authors:  Amy Baker; Kent J Rohleder; Les A Hanakahi; Gary Ketner
Journal:  J Virol       Date:  2007-04-25       Impact factor: 5.103

4.  Control of mRNA export by adenovirus E4orf6 and E1B55K proteins during productive infection requires E4orf6 ubiquitin ligase activity.

Authors:  Paola Blanchette; Kathrin Kindsmüller; Peter Groitl; Frédéric Dallaire; Thomas Speiseder; Philip E Branton; Thomas Dobner
Journal:  J Virol       Date:  2008-01-09       Impact factor: 5.103

Review 5.  Adenovirus E1B 55-kilodalton protein: multiple roles in viral infection and cell transformation.

Authors:  Andrew N Blackford; Roger J A Grand
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

6.  Distinct requirements of adenovirus E1b55K protein for degradation of cellular substrates.

Authors:  Rachel A Schwartz; Seema S Lakdawala; Heather D Eshleman; Matthew R Russell; Christian T Carson; Matthew D Weitzman
Journal:  J Virol       Date:  2008-07-09       Impact factor: 5.103

7.  Inhibition of the ubiquitin-proteasome system prevents vaccinia virus DNA replication and expression of intermediate and late genes.

Authors:  P S Satheshkumar; Luis C Anton; Patrick Sanz; Bernard Moss
Journal:  J Virol       Date:  2009-01-07       Impact factor: 5.103

8.  The adenovirus E1B 55-kilodalton and E4 open reading frame 6 proteins limit phosphorylation of eIF2alpha during the late phase of infection.

Authors:  Megan E Spurgeon; David A Ornelles
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

9.  RUNX1 permits E4orf6-directed nuclear localization of the adenovirus E1B-55K protein and associates with centers of viral DNA and RNA synthesis.

Authors:  Leslie J Marshall; Amy C Moore; Misao Ohki; Issay Kitabayashi; David Patterson; David A Ornelles
Journal:  J Virol       Date:  2008-04-16       Impact factor: 5.103

10.  Differential requirements of the C terminus of Nbs1 in suppressing adenovirus DNA replication and promoting concatemer formation.

Authors:  Seema S Lakdawala; Rachel A Schwartz; Kevin Ferenchak; Christian T Carson; Brian P McSharry; Gavin W Wilkinson; Matthew D Weitzman
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.